Evaxion Posts Three-Year Data for Personalized Melanoma Vaccine EVX-01
Evaxion Biotech reports three-year follow-up data for EVX-01, its AI-designed personalized therapeutic vaccine for melanoma, extending durability evidence.
Topic
Personalized Cancer Vaccine
Topic
Personalized Cancer Vaccine
Evaxion Brings Three-Year EVX-01 Melanoma Data to ESMO 2026
Evaxion will present three-year Phase 2 follow-up on its personalized neoantigen vaccine EVX-01 in advanced melanoma at ESMO 2026…
Moderna and Merck Present Phase 3 Melanoma Data on Personalized Cancer Vaccine
Moderna and Merck present Phase 3 melanoma findings for their personalized mRNA cancer vaccine; endpoints, effect sizes and filin…
AI-Designed Personalized mRNA Therapy Cuts Melanoma Recurrence Risk
An AI-designed personalized mRNA therapy has reduced melanoma recurrence, metastasis and death, BioXconomy reports; effect sizes…
Evaxion to Present New EVX-01 Immune Data at SITC 2026
Evaxion will present comprehensive immune profiling of EVX-01 plus pembrolizumab at SITC on Nov. 6–7, after a 75% two-year ORR in…